So RAC is now basically a pre-clinical stage company? Wasn't the original strategy to compile a data package and position RAC for a takeover bid, yet now they intend to build a pipeline and partner? Nobody should underestimate how risky these pre-clinical studies are. It only takes a single adverse finding in the toxicology study to act as major set back, just look at the recent setbacks for NYR and NSB.
Ann: Race Strategic Update August 2023, page-72
-
- There are more pages in this discussion • 521 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
-0.005(0.27%) |
Mkt cap ! $309.9M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.86 | $1.79 | $157.7K | 86.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5623 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |